If approved in this population, the addition of FLT3 inhibitors will add to recent approvals for of gentuzumab ozogamicin and liposomal cytarabine and daunorubicin for newly diagnosed and secondary-AML, respectively. The gene discussed is FLT3; the disease is acute myeloid leukemia.